TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02811289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirbetriq (Mirabegron)
Description: 50mg of Mirabegron will be administered orally at time 0 in protocol A.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cold exposure
Description: Acute cold exposure protocol using a water-conditioned cooling suit will be applied from time 120 to 300 min in protocol B

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: injection of 18FDG
Description: I.v. injection of 18-fluorodeoxyglucose (18FDG) will be performed at time 270 min, followed by 30 min dynamic PET/CT scanning

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: injection of 18FDG
Description: I.v. injection of 18-fluorodeoxyglucose (18FDG) will be performed at time 270 min, followed by 30 min dynamic PET/CT scanning

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: injection of 11C-acetate
Description: i.v. injection of 11C-acetate will be performed, followed by 20 min dynamic PET/CT scanning

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: injection of 11C-acetate
Description: i.v. injection of 11C-acetate will be performed, followed by 20 min dynamic PET/CT scanning

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: [3-3H]-glucose
Description: i.v. administration of 1.5 uCi/min of \[3-3H\]-glucose

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [3-3H]-glucose
Description: i.v. administration of 1.5 uCi/min of \[3-3H\]-glucose

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: [U-13C]-palmitate
Description: i.v. administration of 0.08 umol/kg/min of \[U-13C\]-palmitate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [U-13C]-palmitate
Description: i.v. administration of 0.08 umol/kg/min of \[U-13C\]-palmitate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2H-Glycerol
Description: i.v. administration of 0.05 µmol/kg/min of 2H-glycerol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2H-Glycerol
Description: i.v. administration of 0.05 µmol/kg/min of 2H-glycerol
Study: NCT01684826

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Angiographic run with new algorithm and low dose (50% dose)
Description: Angiographic run with new algorithm and low dose (50% lower dose compared to Xper)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Angiographic run with predecessor algorithm and dose (100%)
Description: Angiographic run with predecessor algorithm and dose (100% dose)
Study: NCT03715543

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection of the Greater Splanchnic Nerve
Description: Video-Assisted Thoracoscopic Surgery (VATS) is performed under general anesthesia using existing, CE marked instrumentation. Two or more 5 mm incisions are used to pass a tiny video camera and a single dissecting instrument into the chest. These small ports are advantageous because the chance for infection and wound dehiscence are drastically reduced. This allows for a faster recovery by the patient and a greater chance for the wound to heal.~In the procedure the GSN will be identified visually or through stimulation-induced hemodynamic reflex. The GSN will then be ablated using standard techniques. If there are multiple branches of the GSN, each branch will be systematically identified and ablated.
Study: NCT04612088

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Dissonance
Description: A blood sample will be taken before the first take of the multivitamins and at the end of the intervention to measure: Hemoglobin, Calcium, Phosphorous, Iron, Copper, Zinc, Vitamin D, and Folate.~During the three months of the intervention, the intervention group will receive one psycho-educative session and five Cognitive Dissonance sessions.~Several tests will be applied to the patients at the beginning of the program and after the sessions to measure: patient knowledge and adherence to the multivitamin, self-efficacy, self-care, and Psycho-pathological symptoms.~The No intervention group on the wait list will receive the five Cognitive Dissonance sessions after the three months of the study.
Study: NCT00843986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conivaptan
Description: Premix bag

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Premix bag
Study: NCT02032524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avalglucosidase Alfa
Description: Pharmaceutical form: lyophilized powder reconstituted for infusion Route of administration: intravenous
Study: NCT01901328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-5945

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03191786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Description: Atezolizumab will be administered via IV infusion once every three weeks (QW3).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Vinorelbine will be administered per relevant local guidelines and Summary of Product Characteristics (SmPC) management.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered per relevant local guidelines and SmPC management.
Study: NCT01719575

Intervention type: DRUG
Group type: OTHER
Intervention: Motilitone

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Study: NCT04188158

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: CAPECITABINE AND OXALIPLATIN
Description: Intervention Group: Neoadjuvant chemotherapy ( 3 cycles Capecitabine and oxaliplatin) + surgery + adjuvant chemotherapy (5 cycles Capecitabine and oxaliplatin)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CAPECITABINE AND OXALIPLATIN
Description: Intervention Group: Neoadjuvant chemotherapy ( 3 cycles Capecitabine and oxaliplatin) + surgery + adjuvant chemotherapy (5 cycles Capecitabine and oxaliplatin)
Study: NCT01804855

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: W82GO
Description: MDT delivered obesity intervention integrating behavioural change methods in order to reduce obesity; improve nutrition; increase physical activity; improve sleep; reduce sedentarism and increase self-esteem
Study: NCT01791751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomifene Citrate
Description: Clomiphene citrate 100 mg daily for 5 days
Study: NCT00835263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: 200 mg Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamictal®
Description: 200 mg Tablet
Study: NCT04504617

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition education intervention to enhance complementary feeding practices
Description: The intervention consist of a six-week nutrition education intervention developed following the DESIGN procedure and the Socio-Cognitive Theory. The intervention consisted of six three-hour weekly sessions that covered topics such as 1) importance and benefits of exclusive and continuing breastfeeding; 2) nutrition for lactating mothers; 3) importance and benefits of complementary feeding practices; 4) risks for starting complementary feeding too early or too late; 5) complementary feeding practices for each age group (6-8, 9-11, and 12-24); 6) importance and benefits of dietary diversity; 7) importance of animal-source foods; 8) importance and benefits of following water, sanitation, and hygiene practices; 9) food safety practices when preparing meals; and 10) the recommended hand-washing protocol. Each lesson was designed to provide a lecture, a discussion using counseling cards, a cooking demonstration with tasting session, and key messages.
Study: NCT03620682

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching sessions
Description: Participants receive three 30-minute phone sessions with a doctorate-level therapist over the course of one month. These sessions are skills-based and focus on improving participants' problem solving through cognitive-behavioral techniques. Participants are allowed to text the therapist between sessions for information and support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile applications
Description: Participants will have access to 3 mobile apps for the duration of the study, and after it ends. One app will push participants a daily, self-reflective survey to complete, and a daily motivational or instructional tip to rate. Other apps will provide education and exercises on various aspects of mental health and wellness, such as sleep and relaxation.
Study: NCT04504617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education intervention to enhance complementary feeding practices
Description: The intervention consist of a six-week nutrition education intervention developed following the DESIGN procedure and the Socio-Cognitive Theory. The intervention consisted of six three-hour weekly sessions that covered topics such as 1) importance and benefits of exclusive and continuing breastfeeding; 2) nutrition for lactating mothers; 3) importance and benefits of complementary feeding practices; 4) risks for starting complementary feeding too early or too late; 5) complementary feeding practices for each age group (6-8, 9-11, and 12-24); 6) importance and benefits of dietary diversity; 7) importance of animal-source foods; 8) importance and benefits of following water, sanitation, and hygiene practices; 9) food safety practices when preparing meals; and 10) the recommended hand-washing protocol. Each lesson was designed to provide a lecture, a discussion using counseling cards, a cooking demonstration with tasting session, and key messages.
Study: NCT03637764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study: NCT01804855

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smartphone application
Description: Behavior change smartphone application for adolescents aiming to reduce obesity
Study: NCT03019055

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)
Description: CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.~Phase 1 Dose Level 0: 2.5 x10\^5 CAR-20/19-T cells/kg (starting dose level)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg)
Description: CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.~Phase 1 Dose Level 1: 7.5 x10\^5 CAR-20/19-T cells/kg
Study: NCT00634322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucarpidase
Description: IV dose based on weight, two doses given for 5 minutes, 24 hours apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucarpidase
Description: IV dose based on weight, two doses given for 5 minutes, 24 hours apart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin
Description: IV or po given every 6 hours
Study: NCT03019055

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg)
Description: CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.~Phase 1 Dose Level 2: 2.5 x10\^6 CAR-20/19-T cells/kg (goal cell dose)~Phase 1b Expansion Dose Level: 2.5 x 10\^6 cells/kg (single infusion)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)
Description: CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.
Study: NCT00344370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: Pitavastatin 4 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 40 mg
Study: NCT03160144

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open lung approach
Study: NCT01024244

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered po BID, prior to morning and evening meals for 12 weeks.
Study: NCT02043860

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Marrow Irradiation
Description: Subjects in this trial will receive total body irradiation (3Gy) per day for up to four days and as little as one day. Total IMT doses: 3Gy, 6Gy, 9Gy, or 12Gy.
Study: NCT01024244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2599506
Description: Administered po for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2599506
Description: Administered po for 12 weeks
Study: NCT03637764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study: NCT02043860

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Transplant
Description: Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning with escalating doses of total marrow irradiation prior to autologous stem cell rescue.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning therapy prior to transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim (G-CSF)
Description: Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC \> 1000/mm\^3 over period of 3 days.
Study: NCT02318979

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Otto Bock prosthesis
Description: Participants will run using the Otto Bock prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
Study: NCT01495819

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 5cc's of saline give at least once.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: (0.0125, 0.025, 0.0.5, 0.1 and 0.2 mg/70 kg or about 0.18, 0.36, 0.7, 1.4 and 2.8 µg/kg).
Study: NCT03831139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TIM&SARA
Study: NCT01198964

Intervention type: PROCEDURE
Intervention: Low-level cortical stimulation
Description: A couple of electrodes will be stimulated (at a lower level than the stimulation used for standard care) over a period of 4-12 hours based on the signals defined by the motor or language task.
Study: NCT02017444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD4017
Study: NCT02318979

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Otto Bock prosthesis
Description: Participants will run using the Otto Bock prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ossur prosthesis
Description: Participants will run using the Ossur prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ossur prosthesis
Description: Participants will run using the Ossur prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freedom Innovations prosthesis
Description: Participants will run using the Freedom Innovations prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
Study: NCT02017444

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo (matched to AZD4017 arm)
Study: NCT04577768

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tDCS 2 mA
Description: anodal high definition transcranial direct current stimulation of the right primary motor cortex with an intensity of 2 mA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tDCS 1.5 mA
Description: anodal high definition transcranial direct current stimulation of the right primary motor cortex with an intensity of 1.5 mA
Study: NCT02318979

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freedom Innovations prosthesis
Description: Participants will run using the Freedom Innovations prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
Study: NCT02037074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: EVP-6308
Description: Arms 1, 2, 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: EVP-6308
Description: Arms 1, 2, 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: EVP-6308
Description: Arms 1, 2, 3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Arm 4
Study: NCT01461837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD34 selected T-cell depleted allogeneic SCT
Description: Hydroxyurea (60 mg/kg/day) and azathioprine (3 mg/kg/day) day -59 to day -11; fludarabine (30 mg/m2) Days -17, -16, -15, -14, -13; busulfan (3.2 mg/kg/day) Days -12, -11, -10, -9; thiotepa (10 mg/kg IV) day -8; cyclophosphamide (50 mg/kg) Days -7, -6, -5, -4; TLI on day -3; rabbit ATG (2.0 mg/kg/day) day -5,-4,-3, and -2; Stem Cell infusion day 0
Study: NCT03795909

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ruxolitinib
Description: Ruxolitinib （2.5 mg twice daily for patients if the age\<14 years and the weight \<25kg，5 mg twice daily for patients if the age\<14 years and the weight≥25kg, 10mg twice daily for patients if the age ≥14 years and\<18 years）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib （2.5 mg twice daily for patients if the age\<14 years and the weight \<25kg，5 mg twice daily for patients if the age\<14 years and the weight≥25kg, 10mg twice daily for patients if the age ≥14 years and\<18 years）

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone (10mg/m2.d) delayes for the first 2 weeks（form week 1 to 2),(5mg/m2.d) from week 3 to 4，(2.5mg/m2.d) from week 5 to 6），1.25mg/m2.d for week 7，and dropped off on week 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone (10mg/m2.d) delayes for the first 2 weeks（form week 1 to 2),(5mg/m2.d) from week 3 to 4，(2.5mg/m2.d) from week 5 to 6），1.25mg/m2.d for week 7，and dropped off on week 8.
Study: NCT01104012

Intervention type: BIOLOGICAL
Intervention: Classification as asthmatic or rhinitis only via proteomic analysis
Description: Proteomic profiles are established for each patient using plasma and serum samples

Intervention type: BIOLOGICAL
Intervention: Classification as asthmatic or rhinitis only according to a metacholine test
Description: A positive metacholine test indicating bronchial hyperresponsiveness is currently our Gold Standard for diagnosing asthma.
Study: NCT03451968

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: amino acid tracer injection for metabolism analysis
Description: the intervention includes injecting stable amino acid tracers in order to evaluate differences in processing of amino acid in critically ill patients compared to a normal population.~after injection 5 ml of blood will be drawn at time 0, 2, 5, 10, 15, 20, 30, 40, 50, 60, 90, 120, 150, 180 minutes from the start of the study, a total of 14 blood samples (70 cc).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: amino acid tracer injection for metabolism analysis
Description: the intervention includes injecting stable amino acid tracers in order to evaluate differences in processing of amino acid in critically ill patients compared to a normal population.~after injection 5 ml of blood will be drawn at time 0, 2, 5, 10, 15, 20, 30, 40, 50, 60, 90, 120, 150, 180 minutes from the start of the study, a total of 14 blood samples (70 cc).
Study: NCT01824004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Study: NCT03277274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-954
Description: TAK-954 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-954
Description: TAK-954 intravenous infusion.
Study: NCT04577768

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: HD-tDCS sham
Description: sham stimulation of the right primary motor cortex
Study: NCT03787758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-718
Description: SAGE-718
Study: NCT02158507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Veliparib + Lapatinib
Description: Treatment cannot be in administered conjunction with other chemotherapy, targeted therapy, radiation therapy, or other investigational drugs.
Study: NCT03739554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYC065
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: oral capsule
Study: NCT02562885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acoustic pulses
Description: Acoustic pulses applied during NREM sleep slow waves Up-phase or Down-phase. The acoustic stimulus will be delivered by speakers with a volume of about 50 dB.
Study: NCT01373229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide + Plerixafor (+ Rituximab)
Description: 1. Lenalidomide 5mg by mouth (PO) daily beginning cycle 1 day 1.~2. Stage 1: increase by 2.5mg every 7 days to a maximum dose of 10mg.~3. Stage 2: plerixafor will be added after 28 days of 10mg dose maintenance and white blood cell count (WBC) \<100.0 x 109 / L.~4. Dose cohorts of escalating subcutaneous (SC) thrice weekly plerixafor with continuous 10mg lenalidomide:~   * Cohort 1: 0.24 mg/kg~  * Cohort 2: 0.32 mg/kg~  * Cohort 3: 0.42 mg/kg~  * Cohort 4: 0.54 mg/kg~5. Stage 3: Rituximab 375mg/m2 will be added on day 1 of cycles 5-12, day 1 of combination therapy for subjects with PR.~6. Subjects will then continue single agent lenalidomide until disease progression.